Eikonoklastes Therapeutics has licensed and is developing a state of the art immune conjugate technology targeting tissue factor for the treatment of solid tumors and other pathologic conditions. The immune conjugate is engineered with a natural high affinity ligand for tissue factor, conjugated to an IgG3 Fc. This allows the compound to bind to the tumor cells, neovasculature supplying blood to the tumors, and the tumor stem ...
Eikonoklastes Therapeutics has licensed and is developing a state of the art immune conjugate technology targeting tissue factor for the treatment of solid tumors and other pathologic conditions. The immune conjugate is engineered with a natural high affinity ligand for tissue factor, conjugated to an IgG3 Fc. This allows the compound to bind to the tumor cells, neovasculature supplying blood to the tumors, and the tumor stem cells, to trigger complement activation (CDC) and antibody dependent cellular cytotoxicity (ADCC) killing of the pathologic cells. This approach is expected to provide potency and selectivity with minimal side effects.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.